nodes	percent_of_prediction	percent_of_DWPC	metapath
Naloxone—TLR4—prostate cancer	0.255	0.702	CbGaD
Naloxone—ESR1—prostate cancer	0.0714	0.197	CbGaD
Naloxone—ESR1—Estramustine—prostate cancer	0.0549	0.13	CbGbCtD
Naloxone—CYP3A4—prostate cancer	0.0365	0.101	CbGaD
Naloxone—ESR1—Estrone—prostate cancer	0.0354	0.0838	CbGbCtD
Naloxone—ESR1—Ethinyl Estradiol—prostate cancer	0.0315	0.0747	CbGbCtD
Naloxone—ESR1—Conjugated Estrogens—prostate cancer	0.0231	0.0548	CbGbCtD
Naloxone—SLCO1A2—Estrone—prostate cancer	0.0224	0.0531	CbGbCtD
Naloxone—ESR1—Estradiol—prostate cancer	0.0203	0.0481	CbGbCtD
Naloxone—ALB—Abiraterone—prostate cancer	0.016	0.038	CbGbCtD
Naloxone—CYP2C8—Nilutamide—prostate cancer	0.015	0.0354	CbGbCtD
Naloxone—SLCO1A2—Conjugated Estrogens—prostate cancer	0.0147	0.0348	CbGbCtD
Naloxone—SLCO1A2—Estradiol—prostate cancer	0.0129	0.0305	CbGbCtD
Naloxone—CYP2C8—Abiraterone—prostate cancer	0.0124	0.0293	CbGbCtD
Naloxone—ALB—Estrone—prostate cancer	0.0116	0.0275	CbGbCtD
Naloxone—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0115	0.0273	CbGbCtD
Naloxone—SLCO1A2—Prednisone—prostate cancer	0.0111	0.0262	CbGbCtD
Naloxone—ABCB1—Estramustine—prostate cancer	0.00941	0.0223	CbGbCtD
Naloxone—CYP2C8—Cabazitaxel—prostate cancer	0.00917	0.0217	CbGbCtD
Naloxone—CYP2C8—Ethinyl Estradiol—prostate cancer	0.00799	0.0189	CbGbCtD
Naloxone—ALB—Estradiol—prostate cancer	0.00666	0.0158	CbGbCtD
Naloxone—ABCB1—Cabazitaxel—prostate cancer	0.00621	0.0147	CbGbCtD
Naloxone—CYP3A4—Bicalutamide—prostate cancer	0.00607	0.0144	CbGbCtD
Naloxone—ABCB1—Estrone—prostate cancer	0.00607	0.0144	CbGbCtD
Naloxone—ALB—Prednisone—prostate cancer	0.00573	0.0136	CbGbCtD
Naloxone—CYP3A4—Estramustine—prostate cancer	0.00564	0.0134	CbGbCtD
Naloxone—ABCB1—Ethinyl Estradiol—prostate cancer	0.00541	0.0128	CbGbCtD
Naloxone—CYP2C8—Estradiol—prostate cancer	0.00515	0.0122	CbGbCtD
Naloxone—CYP3A4—Flutamide—prostate cancer	0.00503	0.0119	CbGbCtD
Naloxone—CYP3A4—Abiraterone—prostate cancer	0.00503	0.0119	CbGbCtD
Naloxone—TLR4—prostate gland—prostate cancer	0.00411	0.15	CbGeAlD
Naloxone—ABCB1—Conjugated Estrogens—prostate cancer	0.00397	0.00939	CbGbCtD
Naloxone—CYP3A4—Cabazitaxel—prostate cancer	0.00372	0.0088	CbGbCtD
Naloxone—CYP3A4—Estrone—prostate cancer	0.00363	0.0086	CbGbCtD
Naloxone—ABCB1—Mitoxantrone—prostate cancer	0.00361	0.00854	CbGbCtD
Naloxone—ABCB1—Estradiol—prostate cancer	0.00348	0.00825	CbGbCtD
Naloxone—CYP2C8—Etoposide—prostate cancer	0.00336	0.00796	CbGbCtD
Naloxone—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00324	0.00767	CbGbCtD
Naloxone—ABCB1—Prednisone—prostate cancer	0.003	0.00709	CbGbCtD
Naloxone—CYP3A4—Conjugated Estrogens—prostate cancer	0.00238	0.00563	CbGbCtD
Naloxone—ABCB1—Etoposide—prostate cancer	0.00227	0.00539	CbGbCtD
Naloxone—CYP3A4—Mitoxantrone—prostate cancer	0.00216	0.00512	CbGbCtD
Naloxone—TLR4—bone marrow—prostate cancer	0.00212	0.0774	CbGeAlD
Naloxone—CYP3A4—Estradiol—prostate cancer	0.00209	0.00494	CbGbCtD
Naloxone—ABCB1—Docetaxel—prostate cancer	0.00208	0.00493	CbGbCtD
Naloxone—TLR4—testis—prostate cancer	0.00181	0.0662	CbGeAlD
Naloxone—CREB1—prostate gland—prostate cancer	0.00181	0.0661	CbGeAlD
Naloxone—CYP3A4—Prednisone—prostate cancer	0.00179	0.00425	CbGbCtD
Naloxone—ABCB1—Doxorubicin—prostate cancer	0.00155	0.00367	CbGbCtD
Naloxone—OPRK1—prostate gland—prostate cancer	0.00137	0.0501	CbGeAlD
Naloxone—CYP3A4—Etoposide—prostate cancer	0.00136	0.00323	CbGbCtD
Naloxone—CREB1—epithelium—prostate cancer	0.00133	0.0486	CbGeAlD
Naloxone—TLR4—lymph node—prostate cancer	0.00131	0.048	CbGeAlD
Naloxone—CYP3A4—Docetaxel—prostate cancer	0.00125	0.00295	CbGbCtD
Naloxone—CREB1—renal system—prostate cancer	0.00123	0.0451	CbGeAlD
Naloxone—CREB1—urethra—prostate cancer	0.00121	0.0443	CbGeAlD
Naloxone—CYP3A4—urine—prostate cancer	0.00111	0.0405	CbGeAlD
Naloxone—OPRD1—renal system—prostate cancer	0.000974	0.0356	CbGeAlD
Naloxone—CREB1—bone marrow—prostate cancer	0.000932	0.0341	CbGeAlD
Naloxone—CYP3A4—Doxorubicin—prostate cancer	0.00093	0.0022	CbGbCtD
Naloxone—CREB1—testis—prostate cancer	0.000797	0.0291	CbGeAlD
Naloxone—ESR1—prostate gland—prostate cancer	0.000712	0.026	CbGeAlD
Naloxone—Morphine—UGT2B15—prostate cancer	0.000692	0.324	CrCbGaD
Naloxone—CREB1—lymph node—prostate cancer	0.000577	0.0211	CbGeAlD
Naloxone—SLCO1A2—renal system—prostate cancer	0.000572	0.0209	CbGeAlD
Naloxone—ESR1—epithelium—prostate cancer	0.000523	0.0191	CbGeAlD
Naloxone—ESR1—renal system—prostate cancer	0.000485	0.0177	CbGeAlD
Naloxone—OPRM1—testis—prostate cancer	0.000429	0.0157	CbGeAlD
Naloxone—CYP2C8—renal system—prostate cancer	0.0004	0.0146	CbGeAlD
Naloxone—SLCO1A2—testis—prostate cancer	0.00037	0.0135	CbGeAlD
Naloxone—ALB—testis—prostate cancer	0.000368	0.0134	CbGeAlD
Naloxone—ESR1—testis—prostate cancer	0.000314	0.0115	CbGeAlD
Naloxone—ABCB1—prostate gland—prostate cancer	0.000281	0.0103	CbGeAlD
Naloxone—Buprenorphine—CYP2C18—prostate cancer	0.000272	0.128	CrCbGaD
Naloxone—CYP3A4—renal system—prostate cancer	0.000271	0.0099	CbGeAlD
Naloxone—ALB—lymph node—prostate cancer	0.000266	0.00974	CbGeAlD
Naloxone—CYP2C8—testis—prostate cancer	0.000258	0.00945	CbGeAlD
Naloxone—ABCB1—seminal vesicle—prostate cancer	0.000238	0.0087	CbGeAlD
Naloxone—ESR1—lymph node—prostate cancer	0.000227	0.00831	CbGeAlD
Naloxone—ABCB1—epithelium—prostate cancer	0.000207	0.00756	CbGeAlD
Naloxone—Oxycodone—CYP3A5—prostate cancer	0.000195	0.0912	CrCbGaD
Naloxone—ABCB1—renal system—prostate cancer	0.000192	0.00701	CbGeAlD
Naloxone—ABCB1—urethra—prostate cancer	0.000188	0.00688	CbGeAlD
Naloxone—Buprenorphine—CYP3A5—prostate cancer	0.00018	0.084	CrCbGaD
Naloxone—Buprenorphine—CYP2A6—prostate cancer	0.000174	0.0813	CrCbGaD
Naloxone—Vomiting—Cabazitaxel—prostate cancer	0.000146	0.00183	CcSEcCtD
Naloxone—Convulsion—Goserelin—prostate cancer	0.000145	0.00182	CcSEcCtD
Naloxone—Hypertension—Goserelin—prostate cancer	0.000145	0.00182	CcSEcCtD
Naloxone—ABCB1—bone marrow—prostate cancer	0.000145	0.0053	CbGeAlD
Naloxone—Nausea—Degarelix—prostate cancer	0.000145	0.00181	CcSEcCtD
Naloxone—Convulsion—Conjugated Estrogens—prostate cancer	0.000144	0.0018	CcSEcCtD
Naloxone—Gastrointestinal disorder—Ethinyl Estradiol—prostate cancer	0.000144	0.0018	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Goserelin—prostate cancer	0.000142	0.00178	CcSEcCtD
Naloxone—Cardiac disorder—Estradiol—prostate cancer	0.000142	0.00178	CcSEcCtD
Naloxone—Flushing—Estradiol—prostate cancer	0.000142	0.00178	CcSEcCtD
Naloxone—Asthenia—Bicalutamide—prostate cancer	0.000141	0.00177	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—prostate cancer	0.000141	0.00176	CcSEcCtD
Naloxone—Angiopathy—Estradiol—prostate cancer	0.000139	0.00174	CcSEcCtD
Naloxone—Mediastinal disorder—Estradiol—prostate cancer	0.000138	0.00173	CcSEcCtD
Naloxone—Chills—Estradiol—prostate cancer	0.000137	0.00172	CcSEcCtD
Naloxone—Nausea—Cabazitaxel—prostate cancer	0.000136	0.00171	CcSEcCtD
Naloxone—Diarrhoea—Bicalutamide—prostate cancer	0.000135	0.00169	CcSEcCtD
Naloxone—Nervous system disorder—Goserelin—prostate cancer	0.000134	0.00168	CcSEcCtD
Naloxone—Mental disorder—Estradiol—prostate cancer	0.000134	0.00168	CcSEcCtD
Naloxone—Tachycardia—Goserelin—prostate cancer	0.000134	0.00167	CcSEcCtD
Naloxone—Nervous system disorder—Conjugated Estrogens—prostate cancer	0.000133	0.00167	CcSEcCtD
Naloxone—Skin disorder—Goserelin—prostate cancer	0.000133	0.00167	CcSEcCtD
Naloxone—Hyperhidrosis—Goserelin—prostate cancer	0.000132	0.00166	CcSEcCtD
Naloxone—Tachycardia—Conjugated Estrogens—prostate cancer	0.000132	0.00166	CcSEcCtD
Naloxone—Ventricular tachycardia—Epirubicin—prostate cancer	0.000132	0.00166	CcSEcCtD
Naloxone—Skin disorder—Conjugated Estrogens—prostate cancer	0.000132	0.00165	CcSEcCtD
Naloxone—Abdominal pain—Ethinyl Estradiol—prostate cancer	0.000132	0.00165	CcSEcCtD
Naloxone—Body temperature increased—Ethinyl Estradiol—prostate cancer	0.000132	0.00165	CcSEcCtD
Naloxone—Irritability—Capecitabine—prostate cancer	0.000132	0.00165	CcSEcCtD
Naloxone—Injection site reaction—Epirubicin—prostate cancer	0.000131	0.00165	CcSEcCtD
Naloxone—Hyperhidrosis—Conjugated Estrogens—prostate cancer	0.000131	0.00164	CcSEcCtD
Naloxone—Cardiac arrest—Capecitabine—prostate cancer	0.000131	0.00164	CcSEcCtD
Naloxone—Tension—Estradiol—prostate cancer	0.000131	0.00164	CcSEcCtD
Naloxone—Nervousness—Estradiol—prostate cancer	0.000129	0.00162	CcSEcCtD
Naloxone—Chills—Mitoxantrone—prostate cancer	0.000128	0.0016	CcSEcCtD
Naloxone—Nasopharyngitis—Docetaxel—prostate cancer	0.000127	0.00159	CcSEcCtD
Naloxone—Vomiting—Bicalutamide—prostate cancer	0.000125	0.00157	CcSEcCtD
Naloxone—Tremor—Estradiol—prostate cancer	0.000125	0.00156	CcSEcCtD
Naloxone—ABCB1—testis—prostate cancer	0.000124	0.00453	CbGeAlD
Naloxone—Nasopharyngitis—Capecitabine—prostate cancer	0.000123	0.00154	CcSEcCtD
Naloxone—Paraesthesia—Goserelin—prostate cancer	0.000123	0.00154	CcSEcCtD
Naloxone—Ventricular tachycardia—Doxorubicin—prostate cancer	0.000122	0.00153	CcSEcCtD
Naloxone—Agitation—Estradiol—prostate cancer	0.000122	0.00153	CcSEcCtD
Naloxone—Buprenorphine—CYP2C19—prostate cancer	0.000122	0.0572	CrCbGaD
Naloxone—Dyspnoea—Goserelin—prostate cancer	0.000122	0.00153	CcSEcCtD
Naloxone—Paraesthesia—Conjugated Estrogens—prostate cancer	0.000122	0.00153	CcSEcCtD
Naloxone—Injection site reaction—Doxorubicin—prostate cancer	0.000122	0.00152	CcSEcCtD
Naloxone—Dyspnoea—Conjugated Estrogens—prostate cancer	0.000121	0.00152	CcSEcCtD
Naloxone—Coma—Epirubicin—prostate cancer	0.000121	0.00151	CcSEcCtD
Naloxone—Asthenia—Ethinyl Estradiol—prostate cancer	0.000119	0.0015	CcSEcCtD
Naloxone—Pulmonary oedema—Epirubicin—prostate cancer	0.000118	0.00147	CcSEcCtD
Naloxone—Irritability—Prednisone—prostate cancer	0.000117	0.00147	CcSEcCtD
Naloxone—Gastrointestinal disorder—Conjugated Estrogens—prostate cancer	0.000117	0.00147	CcSEcCtD
Naloxone—Pain—Goserelin—prostate cancer	0.000117	0.00147	CcSEcCtD
Naloxone—Nausea—Bicalutamide—prostate cancer	0.000117	0.00147	CcSEcCtD
Naloxone—Cardiac arrest—Prednisone—prostate cancer	0.000117	0.00146	CcSEcCtD
Naloxone—Pain—Conjugated Estrogens—prostate cancer	0.000116	0.00145	CcSEcCtD
Naloxone—Hypertension—Estradiol—prostate cancer	0.000115	0.00144	CcSEcCtD
Naloxone—Diarrhoea—Ethinyl Estradiol—prostate cancer	0.000114	0.00143	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Estradiol—prostate cancer	0.000113	0.00141	CcSEcCtD
Naloxone—Coma—Doxorubicin—prostate cancer	0.000112	0.0014	CcSEcCtD
Naloxone—Cardiac disorder—Etoposide—prostate cancer	0.00011	0.00138	CcSEcCtD
Naloxone—Flushing—Etoposide—prostate cancer	0.00011	0.00138	CcSEcCtD
Naloxone—Pulmonary oedema—Doxorubicin—prostate cancer	0.000109	0.00136	CcSEcCtD
Naloxone—Abdominal pain—Goserelin—prostate cancer	0.000108	0.00136	CcSEcCtD
Naloxone—Body temperature increased—Goserelin—prostate cancer	0.000108	0.00136	CcSEcCtD
Naloxone—Angiopathy—Etoposide—prostate cancer	0.000107	0.00135	CcSEcCtD
Naloxone—Convulsion—Mitoxantrone—prostate cancer	0.000107	0.00135	CcSEcCtD
Naloxone—Body temperature increased—Conjugated Estrogens—prostate cancer	0.000107	0.00134	CcSEcCtD
Naloxone—Abdominal pain—Conjugated Estrogens—prostate cancer	0.000107	0.00134	CcSEcCtD
Naloxone—Hypertension—Mitoxantrone—prostate cancer	0.000107	0.00134	CcSEcCtD
Naloxone—Mediastinal disorder—Etoposide—prostate cancer	0.000107	0.00134	CcSEcCtD
Naloxone—Nervous system disorder—Estradiol—prostate cancer	0.000107	0.00133	CcSEcCtD
Naloxone—Chills—Etoposide—prostate cancer	0.000106	0.00133	CcSEcCtD
Naloxone—Tachycardia—Estradiol—prostate cancer	0.000106	0.00133	CcSEcCtD
Naloxone—Depression—Capecitabine—prostate cancer	0.000106	0.00133	CcSEcCtD
Naloxone—Vomiting—Ethinyl Estradiol—prostate cancer	0.000106	0.00133	CcSEcCtD
Naloxone—Oxymorphone—CYP3A4—prostate cancer	0.000106	0.0495	CrCbGaD
Naloxone—Skin disorder—Estradiol—prostate cancer	0.000105	0.00132	CcSEcCtD
Naloxone—Hyperhidrosis—Estradiol—prostate cancer	0.000105	0.00132	CcSEcCtD
Naloxone—Hot flush—Epirubicin—prostate cancer	0.000103	0.00129	CcSEcCtD
Naloxone—Menopausal symptoms—Epirubicin—prostate cancer	0.000102	0.00127	CcSEcCtD
Naloxone—Nausea—Ethinyl Estradiol—prostate cancer	9.89e-05	0.00124	CcSEcCtD
Naloxone—Tachycardia—Mitoxantrone—prostate cancer	9.88e-05	0.00124	CcSEcCtD
Naloxone—Asthenia—Goserelin—prostate cancer	9.83e-05	0.00123	CcSEcCtD
Naloxone—Skin disorder—Mitoxantrone—prostate cancer	9.83e-05	0.00123	CcSEcCtD
Naloxone—Hyperhidrosis—Mitoxantrone—prostate cancer	9.78e-05	0.00123	CcSEcCtD
Naloxone—Paraesthesia—Estradiol—prostate cancer	9.75e-05	0.00122	CcSEcCtD
Naloxone—Asthenia—Conjugated Estrogens—prostate cancer	9.74e-05	0.00122	CcSEcCtD
Naloxone—Dyspnoea—Estradiol—prostate cancer	9.68e-05	0.00121	CcSEcCtD
Naloxone—Hot flush—Doxorubicin—prostate cancer	9.5e-05	0.00119	CcSEcCtD
Naloxone—Depression—Prednisone—prostate cancer	9.43e-05	0.00118	CcSEcCtD
Naloxone—Menopausal symptoms—Doxorubicin—prostate cancer	9.41e-05	0.00118	CcSEcCtD
Naloxone—Gastrointestinal disorder—Estradiol—prostate cancer	9.38e-05	0.00117	CcSEcCtD
Naloxone—Diarrhoea—Goserelin—prostate cancer	9.37e-05	0.00117	CcSEcCtD
Naloxone—Pain—Estradiol—prostate cancer	9.29e-05	0.00116	CcSEcCtD
Naloxone—Diarrhoea—Conjugated Estrogens—prostate cancer	9.28e-05	0.00116	CcSEcCtD
Naloxone—Hydrocodone—CYP3A4—prostate cancer	9.24e-05	0.0432	CrCbGaD
Naloxone—Flushing—Docetaxel—prostate cancer	9.14e-05	0.00114	CcSEcCtD
Naloxone—Cardiac disorder—Docetaxel—prostate cancer	9.14e-05	0.00114	CcSEcCtD
Naloxone—Cardiac arrest—Epirubicin—prostate cancer	9.13e-05	0.00114	CcSEcCtD
Naloxone—Paraesthesia—Mitoxantrone—prostate cancer	9.09e-05	0.00114	CcSEcCtD
Naloxone—Dyspnoea—Mitoxantrone—prostate cancer	9.02e-05	0.00113	CcSEcCtD
Naloxone—ABCB1—lymph node—prostate cancer	8.98e-05	0.00328	CbGeAlD
Naloxone—Convulsion—Etoposide—prostate cancer	8.94e-05	0.00112	CcSEcCtD
Naloxone—Angiopathy—Docetaxel—prostate cancer	8.93e-05	0.00112	CcSEcCtD
Naloxone—Hypertension—Etoposide—prostate cancer	8.9e-05	0.00112	CcSEcCtD
Naloxone—Mediastinal disorder—Docetaxel—prostate cancer	8.87e-05	0.00111	CcSEcCtD
Naloxone—Cardiac disorder—Capecitabine—prostate cancer	8.85e-05	0.00111	CcSEcCtD
Naloxone—Flushing—Capecitabine—prostate cancer	8.85e-05	0.00111	CcSEcCtD
Naloxone—Chills—Docetaxel—prostate cancer	8.83e-05	0.00111	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—prostate cancer	8.72e-05	0.00109	CcSEcCtD
Naloxone—Vomiting—Goserelin—prostate cancer	8.71e-05	0.00109	CcSEcCtD
Naloxone—Pain—Mitoxantrone—prostate cancer	8.65e-05	0.00108	CcSEcCtD
Naloxone—Angiopathy—Capecitabine—prostate cancer	8.65e-05	0.00108	CcSEcCtD
Naloxone—Vomiting—Conjugated Estrogens—prostate cancer	8.63e-05	0.00108	CcSEcCtD
Naloxone—Mental disorder—Docetaxel—prostate cancer	8.63e-05	0.00108	CcSEcCtD
Naloxone—Mediastinal disorder—Capecitabine—prostate cancer	8.59e-05	0.00108	CcSEcCtD
Naloxone—Abdominal pain—Estradiol—prostate cancer	8.59e-05	0.00108	CcSEcCtD
Naloxone—Body temperature increased—Estradiol—prostate cancer	8.59e-05	0.00108	CcSEcCtD
Naloxone—Nasopharyngitis—Epirubicin—prostate cancer	8.58e-05	0.00108	CcSEcCtD
Naloxone—Chills—Capecitabine—prostate cancer	8.55e-05	0.00107	CcSEcCtD
Naloxone—Hallucination—Prednisone—prostate cancer	8.45e-05	0.00106	CcSEcCtD
Naloxone—Cardiac arrest—Doxorubicin—prostate cancer	8.45e-05	0.00106	CcSEcCtD
Naloxone—Oxycodone—CYP3A4—prostate cancer	8.43e-05	0.0395	CrCbGaD
Naloxone—Mental disorder—Capecitabine—prostate cancer	8.35e-05	0.00105	CcSEcCtD
Naloxone—Tachycardia—Etoposide—prostate cancer	8.22e-05	0.00103	CcSEcCtD
Naloxone—Skin disorder—Etoposide—prostate cancer	8.18e-05	0.00102	CcSEcCtD
Naloxone—Nausea—Goserelin—prostate cancer	8.14e-05	0.00102	CcSEcCtD
Naloxone—Hyperhidrosis—Etoposide—prostate cancer	8.14e-05	0.00102	CcSEcCtD
Naloxone—Nausea—Conjugated Estrogens—prostate cancer	8.06e-05	0.00101	CcSEcCtD
Naloxone—Abdominal pain—Mitoxantrone—prostate cancer	8e-05	0.001	CcSEcCtD
Naloxone—Body temperature increased—Mitoxantrone—prostate cancer	8e-05	0.001	CcSEcCtD
Naloxone—Nasopharyngitis—Doxorubicin—prostate cancer	7.94e-05	0.000995	CcSEcCtD
Naloxone—Flushing—Prednisone—prostate cancer	7.88e-05	0.000987	CcSEcCtD
Naloxone—Asthenia—Estradiol—prostate cancer	7.79e-05	0.000976	CcSEcCtD
Naloxone—Tremor—Capecitabine—prostate cancer	7.78e-05	0.000974	CcSEcCtD
Naloxone—Buprenorphine—CYP3A4—prostate cancer	7.77e-05	0.0364	CrCbGaD
Naloxone—Angiopathy—Prednisone—prostate cancer	7.7e-05	0.000965	CcSEcCtD
Naloxone—Hydromorphone—CYP3A4—prostate cancer	7.66e-05	0.0358	CrCbGaD
Naloxone—Paraesthesia—Etoposide—prostate cancer	7.56e-05	0.000947	CcSEcCtD
Naloxone—Dyspnoea—Etoposide—prostate cancer	7.5e-05	0.00094	CcSEcCtD
Naloxone—Mental disorder—Prednisone—prostate cancer	7.44e-05	0.000932	CcSEcCtD
Naloxone—Diarrhoea—Estradiol—prostate cancer	7.43e-05	0.000931	CcSEcCtD
Naloxone—Convulsion—Docetaxel—prostate cancer	7.43e-05	0.00093	CcSEcCtD
Naloxone—Hypertension—Docetaxel—prostate cancer	7.4e-05	0.000927	CcSEcCtD
Naloxone—Gastrointestinal disorder—Etoposide—prostate cancer	7.27e-05	0.00091	CcSEcCtD
Naloxone—Asthenia—Mitoxantrone—prostate cancer	7.26e-05	0.00091	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	7.25e-05	0.000908	CcSEcCtD
Naloxone—Pain—Etoposide—prostate cancer	7.2e-05	0.000902	CcSEcCtD
Naloxone—Hypertension—Capecitabine—prostate cancer	7.16e-05	0.000898	CcSEcCtD
Naloxone—Sweating—Epirubicin—prostate cancer	7.09e-05	0.000888	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	7.02e-05	0.000879	CcSEcCtD
Naloxone—Diarrhoea—Mitoxantrone—prostate cancer	6.92e-05	0.000867	CcSEcCtD
Naloxone—Vomiting—Estradiol—prostate cancer	6.91e-05	0.000865	CcSEcCtD
Naloxone—Nervous system disorder—Docetaxel—prostate cancer	6.86e-05	0.000859	CcSEcCtD
Naloxone—Tachycardia—Docetaxel—prostate cancer	6.83e-05	0.000855	CcSEcCtD
Naloxone—Skin disorder—Docetaxel—prostate cancer	6.79e-05	0.000851	CcSEcCtD
Naloxone—Agitation—Prednisone—prostate cancer	6.79e-05	0.000851	CcSEcCtD
Naloxone—Abdominal pain—Etoposide—prostate cancer	6.65e-05	0.000834	CcSEcCtD
Naloxone—Body temperature increased—Etoposide—prostate cancer	6.65e-05	0.000834	CcSEcCtD
Naloxone—Nervous system disorder—Capecitabine—prostate cancer	6.64e-05	0.000832	CcSEcCtD
Naloxone—Tachycardia—Capecitabine—prostate cancer	6.61e-05	0.000828	CcSEcCtD
Naloxone—Skin disorder—Capecitabine—prostate cancer	6.58e-05	0.000824	CcSEcCtD
Naloxone—Sweating—Doxorubicin—prostate cancer	6.56e-05	0.000822	CcSEcCtD
Naloxone—Hyperhidrosis—Capecitabine—prostate cancer	6.55e-05	0.00082	CcSEcCtD
Naloxone—Morphine—CYP3A4—prostate cancer	6.51e-05	0.0305	CrCbGaD
Naloxone—Nausea—Estradiol—prostate cancer	6.45e-05	0.000808	CcSEcCtD
Naloxone—Vomiting—Mitoxantrone—prostate cancer	6.43e-05	0.000806	CcSEcCtD
Naloxone—Convulsion—Prednisone—prostate cancer	6.4e-05	0.000802	CcSEcCtD
Naloxone—Hypertension—Prednisone—prostate cancer	6.38e-05	0.000799	CcSEcCtD
Naloxone—Paraesthesia—Docetaxel—prostate cancer	6.28e-05	0.000787	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	6.25e-05	0.000783	CcSEcCtD
Naloxone—Dyspnoea—Docetaxel—prostate cancer	6.24e-05	0.000781	CcSEcCtD
Naloxone—Flushing—Epirubicin—prostate cancer	6.16e-05	0.000772	CcSEcCtD
Naloxone—Cardiac disorder—Epirubicin—prostate cancer	6.16e-05	0.000772	CcSEcCtD
Naloxone—Paraesthesia—Capecitabine—prostate cancer	6.08e-05	0.000762	CcSEcCtD
Naloxone—Gastrointestinal disorder—Docetaxel—prostate cancer	6.04e-05	0.000757	CcSEcCtD
Naloxone—Asthenia—Etoposide—prostate cancer	6.04e-05	0.000757	CcSEcCtD
Naloxone—Dyspnoea—Capecitabine—prostate cancer	6.04e-05	0.000756	CcSEcCtD
Naloxone—Angiopathy—Epirubicin—prostate cancer	6.03e-05	0.000755	CcSEcCtD
Naloxone—Nausea—Mitoxantrone—prostate cancer	6.01e-05	0.000753	CcSEcCtD
Naloxone—Mediastinal disorder—Epirubicin—prostate cancer	5.99e-05	0.00075	CcSEcCtD
Naloxone—Pain—Docetaxel—prostate cancer	5.98e-05	0.000749	CcSEcCtD
Naloxone—Chills—Epirubicin—prostate cancer	5.96e-05	0.000746	CcSEcCtD
Naloxone—Nervous system disorder—Prednisone—prostate cancer	5.92e-05	0.000741	CcSEcCtD
Naloxone—Tachycardia—Prednisone—prostate cancer	5.89e-05	0.000738	CcSEcCtD
Naloxone—Skin disorder—Prednisone—prostate cancer	5.86e-05	0.000734	CcSEcCtD
Naloxone—Gastrointestinal disorder—Capecitabine—prostate cancer	5.85e-05	0.000732	CcSEcCtD
Naloxone—Hyperhidrosis—Prednisone—prostate cancer	5.83e-05	0.000731	CcSEcCtD
Naloxone—Mental disorder—Epirubicin—prostate cancer	5.82e-05	0.000729	CcSEcCtD
Naloxone—Pain—Capecitabine—prostate cancer	5.79e-05	0.000726	CcSEcCtD
Naloxone—Diarrhoea—Etoposide—prostate cancer	5.76e-05	0.000721	CcSEcCtD
Naloxone—Flushing—Doxorubicin—prostate cancer	5.7e-05	0.000714	CcSEcCtD
Naloxone—Cardiac disorder—Doxorubicin—prostate cancer	5.7e-05	0.000714	CcSEcCtD
Naloxone—Tension—Epirubicin—prostate cancer	5.67e-05	0.000711	CcSEcCtD
Naloxone—Nervousness—Epirubicin—prostate cancer	5.62e-05	0.000703	CcSEcCtD
Naloxone—Angiopathy—Doxorubicin—prostate cancer	5.58e-05	0.000698	CcSEcCtD
Naloxone—Mediastinal disorder—Doxorubicin—prostate cancer	5.54e-05	0.000694	CcSEcCtD
Naloxone—Abdominal pain—Docetaxel—prostate cancer	5.53e-05	0.000693	CcSEcCtD
Naloxone—Body temperature increased—Docetaxel—prostate cancer	5.53e-05	0.000693	CcSEcCtD
Naloxone—Chills—Doxorubicin—prostate cancer	5.51e-05	0.000691	CcSEcCtD
Naloxone—Paraesthesia—Prednisone—prostate cancer	5.42e-05	0.000679	CcSEcCtD
Naloxone—Mental disorder—Doxorubicin—prostate cancer	5.38e-05	0.000674	CcSEcCtD
Naloxone—Abdominal pain—Capecitabine—prostate cancer	5.35e-05	0.000671	CcSEcCtD
Naloxone—Body temperature increased—Capecitabine—prostate cancer	5.35e-05	0.000671	CcSEcCtD
Naloxone—Vomiting—Etoposide—prostate cancer	5.35e-05	0.00067	CcSEcCtD
Naloxone—Agitation—Epirubicin—prostate cancer	5.31e-05	0.000666	CcSEcCtD
Naloxone—Tension—Doxorubicin—prostate cancer	5.25e-05	0.000658	CcSEcCtD
Naloxone—Nervousness—Doxorubicin—prostate cancer	5.2e-05	0.000651	CcSEcCtD
Naloxone—Asthenia—Docetaxel—prostate cancer	5.02e-05	0.000629	CcSEcCtD
Naloxone—Convulsion—Epirubicin—prostate cancer	5.01e-05	0.000627	CcSEcCtD
Naloxone—Nausea—Etoposide—prostate cancer	5e-05	0.000626	CcSEcCtD
Naloxone—Hypertension—Epirubicin—prostate cancer	4.99e-05	0.000625	CcSEcCtD
Naloxone—Agitation—Doxorubicin—prostate cancer	4.92e-05	0.000616	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	4.89e-05	0.000612	CcSEcCtD
Naloxone—Asthenia—Capecitabine—prostate cancer	4.86e-05	0.000609	CcSEcCtD
Naloxone—Diarrhoea—Docetaxel—prostate cancer	4.79e-05	0.0006	CcSEcCtD
Naloxone—Body temperature increased—Prednisone—prostate cancer	4.77e-05	0.000597	CcSEcCtD
Naloxone—Abdominal pain—Prednisone—prostate cancer	4.77e-05	0.000597	CcSEcCtD
Naloxone—Convulsion—Doxorubicin—prostate cancer	4.63e-05	0.000581	CcSEcCtD
Naloxone—Diarrhoea—Capecitabine—prostate cancer	4.63e-05	0.000581	CcSEcCtD
Naloxone—Nervous system disorder—Epirubicin—prostate cancer	4.63e-05	0.00058	CcSEcCtD
Naloxone—Hypertension—Doxorubicin—prostate cancer	4.62e-05	0.000579	CcSEcCtD
Naloxone—Tachycardia—Epirubicin—prostate cancer	4.61e-05	0.000577	CcSEcCtD
Naloxone—Skin disorder—Epirubicin—prostate cancer	4.58e-05	0.000574	CcSEcCtD
Naloxone—Hyperhidrosis—Epirubicin—prostate cancer	4.56e-05	0.000571	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	4.52e-05	0.000567	CcSEcCtD
Naloxone—Vomiting—Docetaxel—prostate cancer	4.45e-05	0.000557	CcSEcCtD
Naloxone—Asthenia—Prednisone—prostate cancer	4.33e-05	0.000542	CcSEcCtD
Naloxone—Vomiting—Capecitabine—prostate cancer	4.31e-05	0.000539	CcSEcCtD
Naloxone—Nervous system disorder—Doxorubicin—prostate cancer	4.28e-05	0.000536	CcSEcCtD
Naloxone—Tachycardia—Doxorubicin—prostate cancer	4.26e-05	0.000534	CcSEcCtD
Naloxone—Skin disorder—Doxorubicin—prostate cancer	4.24e-05	0.000531	CcSEcCtD
Naloxone—Paraesthesia—Epirubicin—prostate cancer	4.24e-05	0.000531	CcSEcCtD
Naloxone—Hyperhidrosis—Doxorubicin—prostate cancer	4.22e-05	0.000529	CcSEcCtD
Naloxone—Dyspnoea—Epirubicin—prostate cancer	4.21e-05	0.000527	CcSEcCtD
Naloxone—Nausea—Docetaxel—prostate cancer	4.16e-05	0.000521	CcSEcCtD
Naloxone—Diarrhoea—Prednisone—prostate cancer	4.13e-05	0.000517	CcSEcCtD
Naloxone—Gastrointestinal disorder—Epirubicin—prostate cancer	4.07e-05	0.00051	CcSEcCtD
Naloxone—Pain—Epirubicin—prostate cancer	4.03e-05	0.000505	CcSEcCtD
Naloxone—Nausea—Capecitabine—prostate cancer	4.02e-05	0.000504	CcSEcCtD
Naloxone—Paraesthesia—Doxorubicin—prostate cancer	3.92e-05	0.000491	CcSEcCtD
Naloxone—Dyspnoea—Doxorubicin—prostate cancer	3.89e-05	0.000488	CcSEcCtD
Naloxone—Vomiting—Prednisone—prostate cancer	3.84e-05	0.000481	CcSEcCtD
Naloxone—Gastrointestinal disorder—Doxorubicin—prostate cancer	3.77e-05	0.000472	CcSEcCtD
Naloxone—Pain—Doxorubicin—prostate cancer	3.73e-05	0.000468	CcSEcCtD
Naloxone—Body temperature increased—Epirubicin—prostate cancer	3.73e-05	0.000467	CcSEcCtD
Naloxone—Abdominal pain—Epirubicin—prostate cancer	3.73e-05	0.000467	CcSEcCtD
Naloxone—Nausea—Prednisone—prostate cancer	3.58e-05	0.000449	CcSEcCtD
Naloxone—Abdominal pain—Doxorubicin—prostate cancer	3.45e-05	0.000432	CcSEcCtD
Naloxone—Body temperature increased—Doxorubicin—prostate cancer	3.45e-05	0.000432	CcSEcCtD
Naloxone—Asthenia—Epirubicin—prostate cancer	3.39e-05	0.000424	CcSEcCtD
Naloxone—Diarrhoea—Epirubicin—prostate cancer	3.23e-05	0.000404	CcSEcCtD
Naloxone—Asthenia—Doxorubicin—prostate cancer	3.13e-05	0.000392	CcSEcCtD
Naloxone—Vomiting—Epirubicin—prostate cancer	3e-05	0.000376	CcSEcCtD
Naloxone—Diarrhoea—Doxorubicin—prostate cancer	2.99e-05	0.000374	CcSEcCtD
Naloxone—Nausea—Epirubicin—prostate cancer	2.8e-05	0.000351	CcSEcCtD
Naloxone—Vomiting—Doxorubicin—prostate cancer	2.78e-05	0.000348	CcSEcCtD
Naloxone—Nausea—Doxorubicin—prostate cancer	2.59e-05	0.000325	CcSEcCtD
Naloxone—OPRD1—Signaling Pathways—PTEN—prostate cancer	1.45e-06	1.37e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CYP19A1—prostate cancer	1.44e-06	1.36e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—APC—prostate cancer	1.43e-06	1.36e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PIK3CG—prostate cancer	1.43e-06	1.36e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—P4HB—prostate cancer	1.43e-06	1.36e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MAP2K1—prostate cancer	1.43e-06	1.35e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PIK3CD—prostate cancer	1.42e-06	1.35e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—TYMS—prostate cancer	1.42e-06	1.34e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IRS1—prostate cancer	1.42e-06	1.34e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—EGF—prostate cancer	1.42e-06	1.34e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—AKT1—prostate cancer	1.41e-06	1.34e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—TYMS—prostate cancer	1.41e-06	1.34e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—AKT1—prostate cancer	1.41e-06	1.33e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CXCL8—prostate cancer	1.41e-06	1.33e-05	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—PIK3CA—prostate cancer	1.41e-06	1.33e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—SERPINE1—prostate cancer	1.41e-06	1.33e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PTEN—prostate cancer	1.4e-06	1.33e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—GSTM1—prostate cancer	1.4e-06	1.33e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—TGFB1—prostate cancer	1.4e-06	1.33e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—IL6—prostate cancer	1.4e-06	1.33e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—GSTM1—prostate cancer	1.39e-06	1.32e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—SLC22A1—prostate cancer	1.39e-06	1.32e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—KRAS—prostate cancer	1.39e-06	1.32e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—RXRA—prostate cancer	1.39e-06	1.31e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—EP300—prostate cancer	1.38e-06	1.31e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—EP300—prostate cancer	1.38e-06	1.3e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—LPL—prostate cancer	1.38e-06	1.3e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—GSK3B—prostate cancer	1.38e-06	1.3e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CDKN1B—prostate cancer	1.38e-06	1.3e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—LPL—prostate cancer	1.37e-06	1.3e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—FGF2—prostate cancer	1.36e-06	1.29e-05	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—AKT1—prostate cancer	1.36e-06	1.29e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—SULT2A1—prostate cancer	1.36e-06	1.29e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—INS—prostate cancer	1.36e-06	1.28e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CASP3—prostate cancer	1.35e-06	1.28e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IL2—prostate cancer	1.35e-06	1.27e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—SRC—prostate cancer	1.34e-06	1.27e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—NOS3—prostate cancer	1.34e-06	1.27e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—SRC—prostate cancer	1.34e-06	1.27e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—IL6—prostate cancer	1.34e-06	1.27e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—EP300—prostate cancer	1.34e-06	1.27e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—MED12—prostate cancer	1.34e-06	1.26e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—COMT—prostate cancer	1.34e-06	1.26e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GSTP1—prostate cancer	1.33e-06	1.26e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CYP1A1—prostate cancer	1.33e-06	1.26e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CREBBP—prostate cancer	1.33e-06	1.26e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GNG5—prostate cancer	1.33e-06	1.25e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—CYP1A1—prostate cancer	1.32e-06	1.25e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—ERCC2—prostate cancer	1.32e-06	1.25e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IGF1—prostate cancer	1.31e-06	1.24e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CCND1—prostate cancer	1.31e-06	1.24e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—ERCC2—prostate cancer	1.31e-06	1.24e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—VEGFA—prostate cancer	1.31e-06	1.24e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—ITPR1—prostate cancer	1.31e-06	1.24e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—VEGFA—prostate cancer	1.31e-06	1.24e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—JAK2—prostate cancer	1.3e-06	1.23e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CTNNB1—prostate cancer	1.3e-06	1.23e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—KRAS—prostate cancer	1.3e-06	1.23e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—STAT3—prostate cancer	1.3e-06	1.23e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—IL6—prostate cancer	1.29e-06	1.22e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—STAT3—prostate cancer	1.29e-06	1.22e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—AKT1—prostate cancer	1.29e-06	1.22e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—PIK3CA—prostate cancer	1.28e-06	1.21e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—NCOA3—prostate cancer	1.28e-06	1.21e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MMP9—prostate cancer	1.27e-06	1.21e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MDM2—prostate cancer	1.27e-06	1.21e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CDKN1A—prostate cancer	1.27e-06	1.2e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MAP2K1—prostate cancer	1.27e-06	1.2e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PTEN—prostate cancer	1.27e-06	1.2e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PIK3CD—prostate cancer	1.26e-06	1.19e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—ERBB2—prostate cancer	1.26e-06	1.19e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—SERPINE1—prostate cancer	1.25e-06	1.18e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—MTHFR—prostate cancer	1.24e-06	1.17e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PIK3CB—prostate cancer	1.24e-06	1.17e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—TYMS—prostate cancer	1.24e-06	1.17e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—AKT1—prostate cancer	1.24e-06	1.17e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—MTHFR—prostate cancer	1.23e-06	1.17e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GSTM1—prostate cancer	1.22e-06	1.16e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—HPGDS—prostate cancer	1.22e-06	1.15e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PPARA—prostate cancer	1.22e-06	1.15e-05	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—MYC—prostate cancer	1.21e-06	1.15e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CYP2C19—prostate cancer	1.21e-06	1.15e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PPARA—prostate cancer	1.21e-06	1.14e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—EP300—prostate cancer	1.21e-06	1.14e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—FGF2—prostate cancer	1.21e-06	1.14e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—MYC—prostate cancer	1.2e-06	1.14e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—TGFB1—prostate cancer	1.2e-06	1.14e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—MYC—prostate cancer	1.2e-06	1.14e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—LPL—prostate cancer	1.2e-06	1.14e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—TGFB1—prostate cancer	1.2e-06	1.13e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—PIK3CA—prostate cancer	1.19e-06	1.13e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—AKT1—prostate cancer	1.19e-06	1.13e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CXCL8—prostate cancer	1.19e-06	1.13e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—NOS3—prostate cancer	1.19e-06	1.13e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GSTT1—prostate cancer	1.18e-06	1.12e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ACHE—prostate cancer	1.18e-06	1.12e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—EGFR—prostate cancer	1.18e-06	1.12e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—SRC—prostate cancer	1.18e-06	1.11e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—EGFR—prostate cancer	1.17e-06	1.11e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CYP2A6—prostate cancer	1.17e-06	1.11e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CDKN1B—prostate cancer	1.16e-06	1.1e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CYP1A1—prostate cancer	1.16e-06	1.1e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—JAK2—prostate cancer	1.16e-06	1.09e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—TP53—prostate cancer	1.15e-06	1.09e-05	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—AKT1—prostate cancer	1.15e-06	1.09e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—ERCC2—prostate cancer	1.15e-06	1.09e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—VEGFA—prostate cancer	1.14e-06	1.08e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CAV1—prostate cancer	1.14e-06	1.08e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CASP3—prostate cancer	1.14e-06	1.08e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IL2—prostate cancer	1.14e-06	1.08e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—CAV1—prostate cancer	1.14e-06	1.08e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—AKR1C3—prostate cancer	1.14e-06	1.08e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—STAT3—prostate cancer	1.13e-06	1.07e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—IL6—prostate cancer	1.13e-06	1.07e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PRKACB—prostate cancer	1.13e-06	1.07e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MDM2—prostate cancer	1.13e-06	1.07e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CYP17A1—prostate cancer	1.12e-06	1.06e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—ERBB2—prostate cancer	1.11e-06	1.05e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—KRAS—prostate cancer	1.11e-06	1.05e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—KRAS—prostate cancer	1.11e-06	1.05e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CCND1—prostate cancer	1.11e-06	1.05e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PIK3CB—prostate cancer	1.1e-06	1.04e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CTNNB1—prostate cancer	1.1e-06	1.04e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.09e-06	1.03e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.09e-06	1.03e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—MTHFR—prostate cancer	1.08e-06	1.02e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MMP9—prostate cancer	1.08e-06	1.02e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CDKN1A—prostate cancer	1.07e-06	1.02e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PTEN—prostate cancer	1.07e-06	1.01e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—NCOA2—prostate cancer	1.07e-06	1.01e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PPARA—prostate cancer	1.06e-06	1e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CXCL8—prostate cancer	1.06e-06	9.99e-06	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MYC—prostate cancer	1.05e-06	9.96e-06	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—TGFB1—prostate cancer	1.05e-06	9.94e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—AKT1—prostate cancer	1.04e-06	9.89e-06	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PIK3CG—prostate cancer	1.04e-06	9.86e-06	CbGpPWpGaD
Naloxone—ALB—Metabolism—PIK3CG—prostate cancer	1.04e-06	9.8e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CDKN1B—prostate cancer	1.03e-06	9.76e-06	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—EGFR—prostate cancer	1.03e-06	9.75e-06	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—PIK3CA—prostate cancer	1.02e-06	9.68e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—EP300—prostate cancer	1.02e-06	9.66e-06	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—PIK3CA—prostate cancer	1.02e-06	9.65e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—SLC5A5—prostate cancer	1.02e-06	9.63e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CASP3—prostate cancer	1.01e-06	9.56e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IL2—prostate cancer	1.01e-06	9.55e-06	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CAV1—prostate cancer	9.96e-07	9.43e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CYP2E1—prostate cancer	9.93e-07	9.4e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—SRC—prostate cancer	9.93e-07	9.4e-06	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PIK3CA—prostate cancer	9.9e-07	9.37e-06	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—TP53—prostate cancer	9.89e-07	9.36e-06	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—TP53—prostate cancer	9.86e-07	9.33e-06	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—INS—prostate cancer	9.86e-07	9.33e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CCND1—prostate cancer	9.84e-07	9.31e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—NQO1—prostate cancer	9.82e-07	9.3e-06	CbGpPWpGaD
Naloxone—ALB—Metabolism—INS—prostate cancer	9.8e-07	9.28e-06	CbGpPWpGaD
Naloxone—ALB—Hemostasis—AKT1—prostate cancer	9.75e-07	9.22e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CTNNB1—prostate cancer	9.74e-07	9.22e-06	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—KRAS—prostate cancer	9.73e-07	9.21e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—TH—prostate cancer	9.68e-07	9.16e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—VEGFA—prostate cancer	9.67e-07	9.15e-06	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CREBBP—prostate cancer	9.66e-07	9.14e-06	CbGpPWpGaD
Naloxone—ALB—Metabolism—CREBBP—prostate cancer	9.6e-07	9.09e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—STAT3—prostate cancer	9.58e-07	9.06e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MMP9—prostate cancer	9.55e-07	9.04e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CDKN1A—prostate cancer	9.52e-07	9.01e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PTEN—prostate cancer	9.5e-07	8.99e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CYP1B1—prostate cancer	9.42e-07	8.91e-06	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PIK3CD—prostate cancer	9.16e-07	8.66e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GGT1—prostate cancer	9.12e-07	8.63e-06	CbGpPWpGaD
Naloxone—ALB—Metabolism—PIK3CD—prostate cancer	9.1e-07	8.62e-06	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PIK3CG—prostate cancer	9.07e-07	8.59e-06	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—IL6—prostate cancer	9.06e-07	8.57e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—EP300—prostate cancer	9.06e-07	8.57e-06	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—IL6—prostate cancer	9.03e-07	8.54e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—NCOA1—prostate cancer	8.98e-07	8.5e-06	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PIK3CA—prostate cancer	8.94e-07	8.46e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MYC—prostate cancer	8.9e-07	8.42e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—TGFB1—prostate cancer	8.88e-07	8.4e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CYP19A1—prostate cancer	8.85e-07	8.38e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—SRC—prostate cancer	8.81e-07	8.33e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—EGFR—prostate cancer	8.7e-07	8.24e-06	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—TP53—prostate cancer	8.65e-07	8.18e-06	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—NOS3—prostate cancer	8.65e-07	8.18e-06	CbGpPWpGaD
Naloxone—ALB—Metabolism—NOS3—prostate cancer	8.6e-07	8.14e-06	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—INS—prostate cancer	8.59e-07	8.13e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—VEGFA—prostate cancer	8.58e-07	8.12e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—RXRA—prostate cancer	8.55e-07	8.09e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—STAT3—prostate cancer	8.49e-07	8.04e-06	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—AKT1—prostate cancer	8.42e-07	7.96e-06	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CREBBP—prostate cancer	8.41e-07	7.96e-06	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—AKT1—prostate cancer	8.35e-07	7.91e-06	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—AKT1—prostate cancer	8.33e-07	7.88e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—COMT—prostate cancer	8.23e-07	7.79e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—KRAS—prostate cancer	8.22e-07	7.78e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GSTP1—prostate cancer	8.19e-07	7.75e-06	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—AKT1—prostate cancer	8.09e-07	7.65e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ITPR1—prostate cancer	8.06e-07	7.63e-06	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PIK3CB—prostate cancer	7.98e-07	7.55e-06	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PIK3CD—prostate cancer	7.98e-07	7.55e-06	CbGpPWpGaD
Naloxone—ALB—Metabolism—PIK3CB—prostate cancer	7.94e-07	7.51e-06	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IL6—prostate cancer	7.92e-07	7.49e-06	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PTGS2—prostate cancer	7.91e-07	7.48e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MYC—prostate cancer	7.89e-07	7.47e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TGFB1—prostate cancer	7.87e-07	7.45e-06	CbGpPWpGaD
Naloxone—ALB—Metabolism—PTGS2—prostate cancer	7.86e-07	7.44e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—EGFR—prostate cancer	7.72e-07	7.3e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—TYMS—prostate cancer	7.62e-07	7.21e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PIK3CA—prostate cancer	7.56e-07	7.15e-06	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—NOS3—prostate cancer	7.53e-07	7.13e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GSTM1—prostate cancer	7.53e-07	7.12e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—LPL—prostate cancer	7.39e-07	6.99e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—TP53—prostate cancer	7.31e-07	6.92e-06	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—AKT1—prostate cancer	7.3e-07	6.91e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—KRAS—prostate cancer	7.29e-07	6.9e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CYP1A1—prostate cancer	7.14e-07	6.75e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ERCC2—prostate cancer	7.08e-07	6.7e-06	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PIK3CB—prostate cancer	6.95e-07	6.58e-06	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PTEN—prostate cancer	6.9e-07	6.53e-06	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PTGS2—prostate cancer	6.89e-07	6.52e-06	CbGpPWpGaD
Naloxone—ALB—Metabolism—PTEN—prostate cancer	6.86e-07	6.49e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PIK3CA—prostate cancer	6.7e-07	6.34e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IL6—prostate cancer	6.69e-07	6.33e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—MTHFR—prostate cancer	6.65e-07	6.3e-06	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—EP300—prostate cancer	6.58e-07	6.22e-06	CbGpPWpGaD
Naloxone—ALB—Metabolism—EP300—prostate cancer	6.54e-07	6.19e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PPARA—prostate cancer	6.53e-07	6.18e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TP53—prostate cancer	6.48e-07	6.13e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—AKT1—prostate cancer	6.17e-07	5.84e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CAV1—prostate cancer	6.14e-07	5.81e-06	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PTEN—prostate cancer	6.01e-07	5.69e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IL6—prostate cancer	5.93e-07	5.61e-06	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—EP300—prostate cancer	5.73e-07	5.42e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PIK3CG—prostate cancer	5.59e-07	5.29e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—AKT1—prostate cancer	5.47e-07	5.18e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—INS—prostate cancer	5.29e-07	5.01e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CREBBP—prostate cancer	5.18e-07	4.91e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PIK3CD—prostate cancer	4.91e-07	4.65e-06	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PIK3CA—prostate cancer	4.87e-07	4.6e-06	CbGpPWpGaD
Naloxone—ALB—Metabolism—PIK3CA—prostate cancer	4.84e-07	4.58e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—NOS3—prostate cancer	4.64e-07	4.39e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PIK3CB—prostate cancer	4.28e-07	4.05e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PTGS2—prostate cancer	4.24e-07	4.02e-06	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PIK3CA—prostate cancer	4.24e-07	4.01e-06	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—AKT1—prostate cancer	3.97e-07	3.76e-06	CbGpPWpGaD
Naloxone—ALB—Metabolism—AKT1—prostate cancer	3.95e-07	3.74e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PTEN—prostate cancer	3.7e-07	3.5e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—EP300—prostate cancer	3.53e-07	3.34e-06	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—AKT1—prostate cancer	3.46e-07	3.28e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PIK3CA—prostate cancer	2.61e-07	2.47e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—AKT1—prostate cancer	2.13e-07	2.02e-06	CbGpPWpGaD
